risperidone has been researched along with Cardiac Diseases in 5 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This open-label, rater-blinded, parallel-group study was designed to evaluate noninferiority of paliperidone palmitate (PP), a once-monthly injectable atypical antipsychotic, to once-biweekly risperidone long-acting injectable (RIS-LAI) in adult Chinese patients with acute schizophrenia." | 9.15 | A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia. ( Gu, N; Li, H; Ning, X; Rui, Q; Xu, H, 2011) |
| "Sertindole did not increase all-cause mortality, but cardiac mortality was higher and suicide attempts may be lower with sertindole." | 6.75 | Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP). ( Crocq, MA; Drici, MD; Everitt, B; Hall, GC; Lader, MH; Le Jeunne, C; Mann, RD; Mittoux, A; Moore, ND; Naber, D; Peuskens, J; Priori, S; Sturkenboom, M; Tanghøj, P; Thibaut, F; Thomas, SH; Toumi, M, 2010) |
| "This open-label, rater-blinded, parallel-group study was designed to evaluate noninferiority of paliperidone palmitate (PP), a once-monthly injectable atypical antipsychotic, to once-biweekly risperidone long-acting injectable (RIS-LAI) in adult Chinese patients with acute schizophrenia." | 5.15 | A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia. ( Gu, N; Li, H; Ning, X; Rui, Q; Xu, H, 2011) |
| "Sertindole did not increase all-cause mortality, but cardiac mortality was higher and suicide attempts may be lower with sertindole." | 2.75 | Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP). ( Crocq, MA; Drici, MD; Everitt, B; Hall, GC; Lader, MH; Le Jeunne, C; Mann, RD; Mittoux, A; Moore, ND; Naber, D; Peuskens, J; Priori, S; Sturkenboom, M; Tanghøj, P; Thibaut, F; Thomas, SH; Toumi, M, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Thomas, SH | 1 |
| Drici, MD | 1 |
| Hall, GC | 1 |
| Crocq, MA | 1 |
| Everitt, B | 1 |
| Lader, MH | 1 |
| Le Jeunne, C | 1 |
| Naber, D | 1 |
| Priori, S | 1 |
| Sturkenboom, M | 1 |
| Thibaut, F | 1 |
| Peuskens, J | 1 |
| Mittoux, A | 1 |
| Tanghøj, P | 1 |
| Toumi, M | 1 |
| Moore, ND | 1 |
| Mann, RD | 1 |
| Correll, CU | 1 |
| Nielsen, J | 1 |
| Li, H | 1 |
| Rui, Q | 1 |
| Ning, X | 1 |
| Xu, H | 1 |
| Gu, N | 1 |
| Silke, B | 1 |
| Campbell, C | 1 |
| King, DJ | 1 |
| Vaillant, F | 1 |
| Turrel, F | 1 |
| Bost, M | 1 |
| Bricca, G | 1 |
| Descotes, J | 1 |
| Bui-Xuan, B | 1 |
| Tabib, A | 1 |
| Manati, W | 1 |
| Timour, Q | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Sertindole Versus Risperidone Safety Outcome Study: a Randomised, Partially-blinded, Parallel-group, Active-controlled, Post-marketing Study[NCT00856583] | Phase 3 | 9,809 participants (Actual) | Interventional | 2002-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The analysis was based on all deaths from the WRT+30 days period using the classification performed by the ISC.~The ISC reviewed and classified those adverse events which resulted in death or hospitalisation or were possible suicide attempts and this review was blinded to exposure. The definition of cardiac death was intentionally wide; sudden or unexplained deaths were assumed to be cardiac if there was no non-cardiac explanation. To ensure consistent evaluation and classification, the ISC decided a priori to classify all instances of self harm as possible suicide." (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 31 |
| Risperidone | 12 |
The analysis was based on all deaths from the WRT+30 days period using the classification based upon the Medical Dictionary for Regulatory Activities (MedDRA) terminology, that is, as reported by the investigator (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 17 |
| Risperidone | 8 |
"The analysis was based on all deaths from the WRT+30 days period using the classification performed by the ISC.~The ISC reviewed and classified those adverse events which resulted in death or hospitalisation or were possible suicide attempts and this review was blinded to exposure. The definition of cardiac death was intentionally wide; sudden or unexplained deaths were assumed to be cardiac if there was no non-cardiac explanation. To ensure consistent evaluation and classification, the ISC decided a priori to classify all instances of self harm as possible suicide." (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 14 |
| Risperidone | 21 |
The analysis was based on all deaths from the WRT+30 days period using the classification based upon MedDRA terminology, that is, as reported by the investigator (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 13 |
| Risperidone | 21 |
"The analysis was based on all deaths from the WRT+30 days period using the classification performed by the ISC.~The ISC reviewed and classified those adverse events which resulted in death or hospitalisation or were possible suicide attempts and this review was blinded to exposure. The definition of cardiac death was intentionally wide; sudden or unexplained deaths were assumed to be cardiac if there was no non-cardiac explanation. To ensure consistent evaluation and classification, the ISC decided a priori to classify all instances of self harm as possible suicide." (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 19 |
| Risperidone | 28 |
The analysis was based on all deaths from the WRT+30 days period using the classification based upon MedDRA terminology, that is, as reported by the investigator (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 34 |
| Risperidone | 32 |
The analysis was based on time from start of study drug until stop of study drug for any reason other than sponsor closure of the study (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 3136 |
| Risperidone | 2597 |
The analysis was based on time from start of study drug to first hospitalisation during the WRT+30 days period (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 174 |
| Risperidone | 149 |
"The analysis was based on all suicides and suicide attempts from the WRT+30 days period using the classification performed by the ISC.~The ISC reviewed and classified those adverse events which resulted in death or hospitalisation or were possible suicide attempts and this review was blinded to exposure. The definition of cardiac death was intentionally wide; sudden or unexplained deaths were assumed to be cardiac if there was no non-cardiac explanation. To ensure consistent evaluation and classification, the ISC decided a priori to classify all instances of self harm as possible suicide." (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 68 |
| Risperidone | 76 |
The analysis was based on all suicides and suicide attempts from the WRT+30 days period using the classification based upon MedDRA terminology, that is, as reported by the investigator (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 43 |
| Risperidone | 65 |
Second primary endpoint: a serious adverse event where the patient was hospitalised and for which the Independent Safety Committee (ISC) classified the event as a cardiac event with documented arrhythmia. The analysis of this outcome was not performed due to low number of events. The presented analysis is a replacement analysis using all cardiac events, including arrhythmias, that required hospitalisation (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 10 |
| Risperidone | 6 |
The analysis was based on all deaths from the Whole Randomised Treatment (WRT)+30 days period and the Only Randomised Treatment (ORT) period, respectively (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) | |
|---|---|---|
| Number of deaths (WRT+30 days) | Number of deaths (ORT) | |
| Risperidone | 61 | 44 |
| Sertindole | 64 | 40 |
3 trials available for risperidone and Cardiac Diseases
| Article | Year |
|---|---|
Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Arrhythmias, Cardiac; Female; Hear | 2010 |
A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Data Interpretation, Statistical; Delayed-Action Preparatio | 2011 |
The potential cardiotoxicity of antipsychotic drugs as assessed by heart rate variability.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Conscious Sedation; Double-Blind Method; Heart Disease | 2002 |
2 other studies available for risperidone and Cardiac Diseases
| Article | Year |
|---|---|
Antipsychotic-associated all-cause and cardiac mortality: what should we worry about and how should the risk be assessed?
Topics: Antipsychotic Agents; Data Interpretation, Statistical; Heart Diseases; Humans; Imidazoles; Indoles; | 2010 |
Role of selenium in heart lesions produced by neuroleptics in the rabbit.
Topics: Animals; Antipsychotic Agents; Down-Regulation; Female; Heart Diseases; Injections, Intramuscular; K | 2008 |